Breast Cancer Cells Response to the Antineoplastic Agents Cisplatin, Carboplatin, and Doxorubicin at the mRNA Expression Levels of Distinct Apoptosis‐Related Genes, Including the New Member, BCL2L12

Abstract:  Most apoptosis‐related genes regulate cellular fate as a response to anticancer drugs. Modulations at the mRNA levels of such genes often correlate with the sensitivity of various types of cancer cells to chemotherapeutic reagents. The drugs cisplatin, carboplatin, and doxorubicin exhibit anticancer activity, the mechanism of which is not yet completely clarified, although they are known to modulate the expression of several genes including apoptosis‐related genes, such as members of the BCL2 (Bcl‐2) family. In order to define the significance of the expression patterns of such genes as a response to anticancer drug cytotoxic activity, we studied the possible alterations in the mRNA expression levels of various apoptosis‐related genes, including the new member, BCL2L12, after cell treatment with distinct anticancer drugs (cisplatin, carboplatin, and doxorubicin), in the breast cancer cell line, MCF‐7. The kinetics of cell toxicity was evaluated by the MTT method, whereas the expression levels of distinct apoptosis‐related genes were analyzed by reverse transcriptase polymerase chain reaction (RT‐PCR), using gene‐specific primers. The percentage of nonviable cells was upregulated with increasing concentrations and cell exposure time to the different anticancer drugs. Distinct modulations of apoptosis‐related genes, at the mRNA level, were also observed. However, further work is required in order to ascertain whether the mRNA expression profile of such genes may provide evidence for their contribution to more specific and sensitive prediction of breast cancer response to treatment and therefore the rationale for individualized, more appropriate, and successful treatment.

[1]  C. S. Lee,et al.  Gene expression profiling in breast cancer: towards individualising patient management , 2005 .

[2]  S. Jeffrey,et al.  Genomics-based prognosis and therapeutic prediction in breast cancer. , 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  M. Mottolese,et al.  Altered Expression of FAS System Is Related to Adverse Clinical Outcome in Stage I-II Breast Cancer Patients Treated with Adjuvant Anthracycline-Based Chemotherapy , 2004, Clinical Cancer Research.

[4]  A. Scorilas,et al.  Cisplatin‐Induced Apoptosis in HL‐60 Human Promyelocytic Leukemia Cells , 2003, Annals of the New York Academy of Sciences.

[5]  A. Scorilas,et al.  Expression of BCL2L12, a new member of apoptosis-related genes, in breast tumors , 2003, Thrombosis and Haemostasis.

[6]  D. Katsaros,et al.  Molecular characterization of a new gene, CEAL1, encoding for a carcinoembryonic antigen-like protein with a highly conserved domain of eukaryotic translation initiation factors. , 2003, Gene.

[7]  John Calvin Reed,et al.  The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  L. Zhang,et al.  Soluble Fas (CD95) is a prognostic factor in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous stem cell transplantation. , 2001, Journal of hematotherapy & stem cell research.

[9]  Miguel Martín,et al.  Platinum compounds in the treatment of advanced breast cancer. , 2001, Clinical breast cancer.

[10]  M. Duffy,et al.  Biochemical markers in breast cancer: which ones are clinically useful? , 2001, Clinical biochemistry.

[11]  L. Ashworth,et al.  Molecular cloning, physical mapping, and expression analysis of a novel gene, BCL2L12, encoding a proline-rich protein with a highly conserved BH2 domain of the Bcl-2 family. , 2001, Genomics.

[12]  J. Crown.  The platinum agents: a role in breast cancer treatment? , 2001, Seminars in oncology.

[13]  S. Edge,et al.  Prognostic factors in breast cancer , 2005 .

[14]  A. Chott,et al.  Fas ligand is expressed in normal breast epithelial cells and is frequently up‐regulated in breast cancer , 2000, The Journal of pathology.

[15]  A. Scorilas,et al.  Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis , 1999, British Journal of Cancer.

[16]  P. Sismondi,et al.  Immunoenzymatically determined pepsinogen C concentration in breast tumor cytosols: an independent favorable prognostic factor in node-positive patients. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  J. Reed,et al.  Bcl-2 Gene Family and Related Proteins in Mammary Gland Involution and Breast Cancer , 1999, Journal of Mammary Gland Biology and Neoplasia.

[18]  A. Scorilas,et al.  Predictive value of c-erbB-2 and cathepsin-D for Greek breast cancer patients using univariate and multivariate analysis. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  P. Lipponen.  Apoptosis in breast cancer: relationship with other pathological parameters. , 1999, Endocrine-related cancer.

[20]  K Vajda,et al.  [Prognostic factors in breast cancer]. , 1998, Orvosi hetilap.

[21]  G. Hortobagyi.  Chemotherapy of breast cancer: a historical perspective. , 1997, Seminars in oncology.

[22]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[23]  A. Scorilas,et al.  Expression analysis of BCL2L12, a new member of apoptosis-related genes, in colon cancer , 2004, Biological chemistry.

[24]  A. Scorilas,et al.  mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin , 2004, Biological chemistry.

[25]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.